CritiTech and
AAIPharma Services Announce Strategic Alliance
to Provide A Novel Drug Delivery Option to Pharmaceutical
and Biotech Companies
July 8, 2010
FOR IMMEDIATE RELEASE
LAWRENCE, KS and WILMINGTON, NC -- AAIPharma
Services Corp., a biopharmaceutical drug product development
and contract manufacturing company, and CritiTech, Inc., a
nanotechnology company that improves the delivery of therapeutic
molecules, announce a strategic alliance to expand the reach
of the CritiTech technology.
This alliance will allow pharmaceutical and
biotech companies to choose a novel drug delivery option in
early animal toxicology and clinical studies where there is
a drug delivery challenge that cannot be solved through conventional
approaches. Drug product development and manufacturing will
be performed by AAIPharma Services, and drug product intermediate
manufacturing will be performed by CritiTech. The two companies
will be connected through AAIPharma Services’ best-in-class
project management expertise.
AAIPharma Services Corp already offers both
its own proprietary drug delivery technologies as well as
other technologies through its alliance partners, such as
Emisphere Inc. The alliance with CritiTech provides a new
drug delivery option for parenteral administration to complement
AAIPharma Services already established oral drug delivery
franchise. CritiTech’s technology aims to improve the
delivery of therapeutic molecules with low aqueous solubility
or poor bioavailability. The key benefit of the CritiTech
technology is the body’s improved ability to absorb
these difficult to formulate drugs. One key differentiator
of the Crititech technology is it allows for parenteral administration
of drugs which previously could not be administered via this
route.
Chief Executive Officer of CritiTech Inc. David
Johnston said, “The Alliance with AAI Pharma services
allows us to share the established CritiTech technology, used
in our Nanotax™ product currently in development, with
a broad range of potential customers. The collaboration with
AAI Pharma services and their outstanding product development
and manufacturing capability allows us to provide additional
drug delivery options throughout the drug product development
cycle and to more fully exploit CritiTech technology.”..
Chief Executive Officer of AAIPharma's Services
L. Lee Karras added, "The alliance with CritiTech allows
us to add a breakthrough drug delivery option for our pharmaceutical
and biotech customers, whether they are developing a new product
or improving an existing product already on the market. The
combination of the CritiTech technology and AAIPharma Service's
best- in- class drug product development and contract manufacturing
services will be of tremendous value to customers. This new
offering is in line with our strategy to become the leading
provider of complex drug development services to the pharmaceutical
and biotechnology industries."
About CritiTech Technologies, Inc.
CritiTech is a technology company that focuses
on a unique and improved delivery of therapeutic molecules
and compounds using its patented nanotechnology. CritiTech’s
technology is licensed from the Department of Chemical Engineering
at the University of Kansas and the Higuchi Biosciences Center.
The technology can be applied to the oral route of administration
as well other delivery pathways, such as buccal, rectal, inhalation,
vaginal or transdermal. CritiTech laboratory operations are
located in Lawrence, Kansas. For more information on the company,
go to www.crititech.com.
About AAIPharma
Services Corp.
AAIPharma Services Corp.
is a leading provider of services that encompass the entire
process of pharmaceutical drug development from discovery
through commercialization. The company specializes in analytical
chemistry, formulation development, clinical packaging, oral
drug delivery and contract manufacturing. AAIPharma Services
serves more than 300 large pharmaceutical and biotechnology
companies throughout North America. It is headquartered in
Wilmington, North Carolina. For more information on the company,
go to www.aaipharma.com.
|
